Clinical Trial Update: Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. [NA]

View source ↗

Summary

A clinical trial evaluating Holmium-166 transarterial radioembolization for unresectable, early-stage hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Holmium-166 transarterial radioembolization

Snippet

Sponsor: Terumo Europe N.V. | Conditions: Hepatocellular Carcinoma | NA | Status: TERMINATED